GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » COGS-to-Revenue

SSY Group (HKSE:02005) COGS-to-Revenue : 0.46 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is SSY Group COGS-to-Revenue?

SSY Group's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$1,455 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$3,130 Mil.

SSY Group's COGS to Revenue for the six months ended in Dec. 2023 was 0.46.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SSY Group's Gross Margin % for the six months ended in Dec. 2023 was 53.51%.


SSY Group COGS-to-Revenue Historical Data

The historical data trend for SSY Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group COGS-to-Revenue Chart

SSY Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.36 0.41 0.45 0.44

SSY Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.43 0.46 0.42 0.46

SSY Group COGS-to-Revenue Calculation

SSY Group's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2843.37 / 6463.009
=0.44

SSY Group's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1454.964 / 3129.852
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SSY Group  (HKSE:02005) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SSY Group's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1454.964 / 3129.852
=53.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


SSY Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of SSY Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SSY Group (HKSE:02005) Business Description

Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines